Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells

• Main Authors: Shaocong Wu, Liwu Fu
• Format: Article
• Language: English
• Published: BMC 2018-02-01
• Series: Molecular Cancer
• Subjects: Tyrosine kinase inhibitor; ABC transporter; Multiple drug resistance; Chemotherapy; Chemosensitizer
• Online Access: http://link.springer.com/article/10.1186/s12943-018-0775-3

Abstract Multidrug resistance (MDR) triggered by ATP binding cassette (ABC) transporter such as ABCB1, ABCC1, ABCG2 limited successful cancer chemotherapy. Unfortunately, no commercial available MDR modulator approved by FDA was used in clinic. Tyrosine kinase inhibitors (TKIs) have been administrated to fight against cancer for decades. Almost TKI was used alone in clinic. However, drug combinations acting synergistically to kill cancer cells have become increasingly important in cancer chemotherapy as an approach for the recurrent resistant disease. Here, we summarize the effect of TKIs on enhancing the efficacy of conventional chemotherapeutic drug in ABC transporter-mediated MDR cancer cells, which encourage to further discuss and study in clinic.